Skip to content
Peptide research

Kisspeptin-10

Also known as Metastin Fragment · KP-10
Category
Hormone & Sexual Health
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

Kisspeptin-10 is a synthetic hormone fragment used experimentally to trigger GnRH and LH/FSH release for fertility research, including IVF triggering and testosterone support. GnRH stimulation and IVF triggering have moderate human support, but amenorrhea reversal and anti-cancer claims are speculative. Repeated dosing can desensitize the reproductive axis, and no long-term human safety data exist. It is not FDA-approved, and WADA explicitly listed kisspeptin and its agonist analogues as prohibited at all times in males from 2024.

Read Full record

Studied uses & evidence

Studied uses(8)

  • GnRH and gonadotropin stimulation

    High

    Multiple human trials confirm IV KP-10 raises LH and pulse frequency.

  • Safer IVF oocyte maturation trigger

    Medium

    Human dose-finding trial used kisspeptin-54, not KP-10, with no head-to-head trigger comparison.

  • Restoration of reproductive function in hypothalamic amenorrhea

    Low

    Small studies with KP-54 increased LH pulsatility, but no restored ovulation or fertility shown.

Evidence limits

Evidence Level
Phase 1-2

Approximately 50 published studies with human data, including ~18 clinical trials or interventional studies. Most involve healthy volunteers or small patient cohorts (10-50 subjects). The largest IVF trial included 60 women. A 2023 JAMA Network Open RCT (n=32) demonstrated efficacy for HSDD. No Phase 3 trials completed. Evidence is strongest for IVF oocyte maturation triggering and GnRH/LH stimulation.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Hormone-sensitive cancers

    High

    Stimulates GnRH -> LH/FSH -> sex hormone production. May promote hormone-dependent tumor growth.

General cautions

  • Pregnancy (except controlled IVF use)

    Absolute

    Disrupts reproductive hormone signaling.

Risk summary(9)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Very short half-life (~4 minutes for KP-10) limits practical clinical utility without continuous infusion

    High
  • Tachyphylaxis with continuous/daily dosing — chronic exposure desensitizes GnRH neurons and paradoxically suppresses gonadotropins

    High
  • No long-term human safety data — all clinical studies involve short-duration exposure

    High
  • Sexual dimorphism in response — minimal effect in follicular-phase women, unpredictable in some populations

    Moderate
  • Not FDA-approved — no standardized pharmaceutical-grade formulations available outside research settings

    High
  • Unregulated products sold online may have variable purity and quality

    High
  • Potential appetite suppression reported anecdotally; interaction with metabolic pathways not fully characterized

    Theoretical
  • Theoretical concern: chronic HPG axis suppression via desensitization could impair fertility if dosed incorrectly

    Theoretical
  • WADA prohibited in males since 2024 — implications for competitive athletes

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.